Mpro Cysteine Protease Inhibitors for Viral Replication
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for viral infections, particularly those caused by coronaviruses like SARS-CoV-2, lack effective inhibitors targeting the main protease (Mpro) enzyme, which is crucial for viral replication and transcription.
Innovation Solution
Development of compounds that act as Mpro cysteine protease inhibitors, specifically formulated as pharmaceutical compositions, to treat or prevent viral infections by targeting the Mpro enzyme, potentially combined with other inhibitors like viral polymerase, protease, fusion, or CYP3A4 inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for viral infections are used, then existing therapeutic options are available, but effective inhibitors targeting the main protease (Mpro) enzyme are lacking
Solution Approach 1:
The patent segments the protease inhibitor molecule into distinct functional regions (amino acid residues at positions P1, P2, P3, etc.) that can be independently optimized. Each residue position can be modified to enhance binding affinity to specific subsites of the Mpro enzyme active site, allowing systematic improvement of inhibitor effectiveness while maintaining the overall molecular framework
Solution Approach 2:
The patent systematically varies chemical parameters of the inhibitor molecules including substituent types (R1, R2, R3 groups), stereochemistry (L/D amino acid configurations), and molecular weight. These parameter changes enable optimization of the balance between Mpro binding affinity (effectiveness) and pharmacokinetic properties (versatility for different administration routes and patient populations)
2Reliability
If small molecule inhibitors of SARS-CoV-2:Mpro are developed, then viral replication can be inhibited, but the complexity of identifying effective compounds increases
Solution Approach 1:
The patent describes a universal molecular framework (Formula I) that can generate multiple effective inhibitors by varying specific substituents while maintaining the core structure that binds to Mpro. This universal framework approach reduces the complexity of compound identification because researchers can systematically explore a focused library of derivatives rather than screening random compounds, while still achieving reliable viral replication inhibition
Solution Approach 2:
The patent performs preliminary structural optimization by pre-defining the core molecular framework and key substituent positions that are known to interact with Mpro active site residues. This preliminary action reduces the search space for effective inhibitors, making the compound identification process less complex while ensuring that generated compounds have the necessary structural features for reliable viral replication inhibition
Data Source
AI summary
Described herein are Mpro cysteine protease inhibitors and methods of utilizing such inhibitors in the treatment of diseases, disorders, or conditions. Also described herein are pharmaceutical compositions containing such compounds.